Next Article in Journal
Intranasal Immunization of Mice with Multiepitope Chimeric Vaccine Candidate Based on Conserved Autotransporters SigA, Pic and Sap, Confers Protection against Shigella flexneri
Next Article in Special Issue
Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database
Previous Article in Journal
Vaccinations and Chronic Diseases: Knowledge, Attitudes, and Self-Reported Adherence among Patients in Italy

Measuring the Benefits of Mass Vaccination Programs in the United States

Independent Computer Scientist, Orange County, CA 92677, USA
Department of Medicine, UC San Diego School of Medicine, La Jolla, CA 92093, USA
Author to whom correspondence should be addressed.
Vaccines 2020, 8(4), 561;
Received: 26 August 2020 / Revised: 21 September 2020 / Accepted: 22 September 2020 / Published: 29 September 2020
Since the late 1940s, mass vaccination programs in the USA have contributed to the significantly reduced morbidity and mortality of infectious diseases. To assist the evaluation of the benefits of mass vaccination programs, the number of individuals who would have suffered death or permanent disability in the USA in 2014, had mass vaccination never been implemented, was estimated for measles, mumps, rubella, tetanus, diphtheria, pertussis, polio, Haemophilus influenzae type b (Hib), hepatitis B, varicella, and human papillomavirus (HPV). The estimates accounted for mortality and morbidity trends observed for these infections prior to mass vaccination and the impact of advances in standard of living and health care. The estimates also considered populations with and without known factors leading to an elevated risk of permanent injury from infection. Mass vaccination prevented an estimated 20 million infections and 12,000 deaths and permanent disabilities in 2014, including 10,800 deaths and permanent disabilities in persons at elevated risk. Though 9000 of the estimated prevented deaths were from liver cirrhosis and cancer, mass vaccination programs have not, at this point, shown empirical impacts on the prevalence of those conditions. Future studies can refine these estimates, assess the impact of adjusting estimation assumptions, and consider additional risk factors that lead to heightened risk of permanent harm from infection. View Full-Text
Keywords: vaccination; disease; mortality; disability; risk vaccination; disease; mortality; disability; risk
MDPI and ACS Style

Magno, H.; Golomb, B. Measuring the Benefits of Mass Vaccination Programs in the United States. Vaccines 2020, 8, 561.

AMA Style

Magno H, Golomb B. Measuring the Benefits of Mass Vaccination Programs in the United States. Vaccines. 2020; 8(4):561.

Chicago/Turabian Style

Magno, Hector, and Beatrice Golomb. 2020. "Measuring the Benefits of Mass Vaccination Programs in the United States" Vaccines 8, no. 4: 561.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop